5 Key Takeaways

• 1

  The SPECTRA trial evaluates the safety and efficacy of 4D-150 gene therapy for diabetic macular edema.

• 2

  4D-150 is a novel intravitreal genetic medicine delivering a dual transgene cassette for aflibercept and VEGF-C inhibition.

• 3

  Interim results show that a single dose of 4D-150 was well tolerated with no serious adverse events or intraocular inflammation.

• 4

  Patients in the high-dose group experienced an average gain of 8.4 letters and a 194 µm reduction in central subfield thickness.

• 5

  The treatment significantly reduced the need for supplemental anti-VEGF injections by 84%, addressing patient concerns about treatment burden.